Physician Quick Search
By Name:
By Specialty:
314-TOP-DOCS
When you need to get the name of one of the nation’s top doctors as close to home as St. Louis, just call 314-TOP-DOCS (314-867-3627) or toll free 1-866-867-3627. This is the physician referral and health information line from Barnes-Jewish Hospital.
Your Healthy Update

Like us on Facebook
Text Size: S M L
Search

Internal Medicine / Oncology

Joel Picus, MD

Current Position
Professor, Medicine
Division of Oncology - Medical Oncology
Section, Medical and Molecular Oncology


Specialty Areas
Gastrointestinal Oncology
Pancreatic Cancer
Hematology
Oncology
Hepatobiliary Pancreatic Cancer
Colon and Rectal Cancer
Genitourinary Oncology

Patients Seen At
Alvin J. Siteman Cancer Center
Center for Advanced Medicine
4921 Parkview Place, B, 7
St. Louis, MO  63110
314-747-9281
Fax:   314-362-7086
View Floor Map  View Campus Map   View Driving Directions

Siteman Cancer Center - South County
5225 MidAmerica Plaza, Main Floor
St. Louis, MO  63129
314 747 1171
View Driving Directions

Mailing Address
Washington University School of Medicine
Department of Internal Medicine
660 S. Euclid Avenue, Campus Box 8056
St. Louis, MO  63110

Academic Office
1st Floor, Wohl Hospital Building
4960 Children's Place, Barnes-Jewish Hospital, South
St. Louis, MO  63110
(314) 362-5737
Fax:   (314) 362-7086

Areas of Clinical Interest
Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

Board Certification
Hematology -- Certified
Internal Medicine -- Certified
Oncology -- Certified

Medical Education
B.A.: Biology, University of Illinois, Urbana, IL, 1979
B.S.: Electrical Engineering, University of Illinois, Urbana, IL, 1979
Medical Degree: Harvard Medical School, Boston, MA, 1984
Residency: Internal Medicine, Duke University Medical Center, 1987
Fellowship: Hematology and Oncology, Cancer Research Institute, University of California, San Francisco, CA, 1991
Hospital Affiliations
Barnes-Jewish Hospital

Honors and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)
Listed in America's Top Doctors, 2007-2012 (Castle & Connolly Ltd.)

Selected or Recent Journal Articles
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013 Jun;31(3):707-13.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):483-92.

Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012 Sep 10;13(5):497-501.

Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37.

Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 1;117(3):526-33.

Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford). 2010 Aug;12(6):418-26.

Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):428-35.

Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8.

Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol. 2008 Oct;19(10):1742-8.

Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR Jr. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg. 2008 Aug;248(2):145-51.

Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007 May;188(5):1201-7.

Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-81.

Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006 Mar;4(4):269-74.

Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer. 2005 Jul 11;93(1):46-53.

David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005 Jun;28(3):277-80. Review.

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Joel Picus.


Washington University Physicians are the medical staff of  Barnes-Jewish Hospital and Children's Hospital - St. Louis Employment   About Us   Top Stories   For Your Protection      Site Map
Copyright 2014 Washington University School of Medicine
Copyright 2014 Washington University School of Medicine